Zevra Therapeutics’ (ZVRA) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report report published on Thursday morning, MarketBeat Ratings reports. The firm currently has a $26.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on ZVRA. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Thursday, August 6th. Maxim Group upped their price objective on Zevra Therapeutics from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Guggenheim reduced their price objective on Zevra Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Finally, Citizens Jmp boosted their target price on Zevra Therapeutics from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, August 6th. Nine analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $27.14.

Zevra Therapeutics Trading Down 0.2%

Shares of ZVRA opened at $11.87 on Thursday. Zevra Therapeutics has a 12-month low of $7.16 and a 12-month high of $15.03. The company has a market cap of $704.84 million, a PE ratio of 12.90 and a beta of 0.91. The stock has a 50-day moving average price of $12.23 and a 200-day moving average price of $10.76.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. The company had revenue of $39.66 million for the quarter, compared to analysts’ expectations of $33.88 million. As a group, analysts predict that Zevra Therapeutics will post 0.72 earnings per share for the current year.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, Director Corey Michael Watton sold 12,300 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the sale, the director directly owned 1,800 shares in the company, valued at $20,250. This represents a 87.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 3.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP grew its holdings in shares of Zevra Therapeutics by 5.2% in the second quarter. Wellington Management Group LLP now owns 164,538 shares of the company’s stock worth $2,359,000 after purchasing an additional 8,121 shares during the last quarter. Globeflex Capital L P purchased a new stake in Zevra Therapeutics during the 2nd quarter valued at $2,752,000. Bank of New York Mellon Corp bought a new stake in Zevra Therapeutics in the 2nd quarter worth $2,846,000. Hennion & Walsh Asset Management Inc. grew its holdings in Zevra Therapeutics by 116.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock worth $5,502,000 after acquiring an additional 206,543 shares during the last quarter. Finally, Quantinno Capital Management LP grew its holdings in Zevra Therapeutics by 114.1% in the 1st quarter. Quantinno Capital Management LP now owns 32,022 shares of the company’s stock worth $298,000 after acquiring an additional 17,065 shares during the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.